• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $INTS

    Intensity Therapeutics Inc.

    Subscribe to $INTS
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IPO Year: 2023

    Exchange: NASDAQ

    Recent Analyst Ratings for Intensity Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Intensity Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

      32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screenedEight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screenedFinal sarcoma data from our first metastatic study and our INVINCIBLE-3 Study design was presented at the annual Connective Tissue Oncology Society Meeting in November 2024Final data from our first neoadjuvant breast cancer study and our INVINCIBLE-4 Study design was presented at the annual San Antonio Breast Cancer Society Meeting in December 2024SHELTON, Conn., March 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology

      3/13/25 4:07:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn., Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces third quarter 2024 financial results and provides a corporate update. Corporate Update INVINCIBLE-3 Study: a Phase 3 open-label, rand

      11/13/24 4:06:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Intensity Therapeutics Inc. SEC Filings

    See more

    Intensity Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form DEFA14A filed by Intensity Therapeutics Inc.

      DEFA14A - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      6/2/25 4:02:41 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Intensity Therapeutics Inc.

      DEF 14A - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      6/2/25 4:01:48 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      5/20/25 4:05:38 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      5/13/25 4:08:01 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Intensity Therapeutics Inc.

      10-Q - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      5/13/25 4:01:20 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      4/25/25 5:24:38 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B4 filed by Intensity Therapeutics Inc.

      424B4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      4/25/25 5:23:53 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Intensity Therapeutics Inc.

      EFFECT - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      4/25/25 12:15:33 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form S-1/A filed by Intensity Therapeutics Inc.

      S-1/A - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      4/24/25 8:01:32 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      4/22/25 8:12:50 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Wesolowski John M

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:21:05 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Dubin Thomas I H

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:11:54 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Donovan Daniel

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:11:09 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Goldberg Mark A

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:10:04 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Leahy Emer

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:09:05 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Wesolowski John M

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:07:32 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President and CEO Bender Lewis H

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:07:10 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Talamo Joseph

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:03:44 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Wesolowski John M

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      10/23/24 4:22:28 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Talamo Joseph

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      10/23/24 4:21:12 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Intensity Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Intensity Therapeutics Inc.

      SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)

      6/7/24 5:29:04 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Intensity Therapeutics Inc.

      SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)

      2/13/24 4:01:30 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Intensity Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

      SHELTON, Conn., May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024. Mr. Dubin will serve as a member of the Audit Committee of the Board. In connection with Mr. Dubin's appointment, the size of the Board was increased from four directors to five. Of these five directors, four are independent pursuant to Nas

      5/15/24 8:01:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

      Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage biopharmaceutical companies SHELTON, Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO). Mr. Talamo will be working at Intensity headquarters as a full time employee. An accomplished executive with more than

      12/12/23 8:01:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Intensity Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

      SHELTON, Conn., May 29, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that the Company will be presenting a Trials in Progress poster outlining its Phase 3 INVINCIBLE-3 clinical trial of INT230-6 for the treatment of metastatic soft tissue sarcomas. The poster will be shown at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting held at McCormick Place in Chicago May 30-June 5, 2025.

      5/29/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

      SHELTON, Conn., May 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral investigational cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces a collaboration to educate patients with early stage breast cancer about potential new therapeutic options with model, author, executive producer, speaker, and breast cancer survivor Christine Handy. The film, Hello Beautiful, an adaptation of Ms. Handy's award-winning novel Walk Beside Me, recently won the Golden Palm Award at

      5/28/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been treatedEuropean Medicines Agency Authorization to initiate INVINCIBLE-4-Study in FranceSHELTON, Conn., May 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces first quarter 2025 financial results and provides a corporate update.

      5/13/25 4:06:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France

      INVINCIBLE-4 (SAKK/66/22) Study continues to recruit patients in eight sites in Switzerland SHELTON, Conn. and BERN, Switzerland, May 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, and The Swiss Group for Clinical Cancer Research SAKK ("SAKK"), a decentralized academic research institute that has been conducting clinical trials of cancer treatments in all major Swiss hospitals since 1965, announced that the European Med

      5/6/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering

      SHELTON, Conn., April 25, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the pricing of its "reasonable best efforts" public offering with participation from certain new and existing institutional and accredited investors for the purchase and sale of 3,133,333 shares of its common stock (or common stock equivalents in lieu thereof) and accompanying Series B-1 common warrants to purchase up to 3,133,333 shar

      4/25/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

      32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screenedEight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screenedFinal sarcoma data from our first metastatic study and our INVINCIBLE-3 Study design was presented at the annual Connective Tissue Oncology Society Meeting in November 2024Final data from our first neoadjuvant breast cancer study and our INVINCIBLE-4 Study design was presented at the annual San Antonio Breast Cancer Society Meeting in December 2024SHELTON, Conn., March 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology

      3/13/25 4:07:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review

      INVINCIBLE-3 Study continues to recruit patients with leiomyosarcoma, liposarcoma and undifferentiated pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S., Canada, Europe and Australia SHELTON, Conn., Jan. 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that following its most recent periodic review meeting, the Data Monitoring Committee (DMC) overseeing the Company's

      1/28/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

      The US FDA, Health Canada, European Medicines Authority, and the Australian Therapeutic Goods Administration authorized the Company's global, randomized Phase 3 study (INVINCIBLE-3) in Metastatic Soft Tissue SarcomaTwenty-three sites are currently contracted in the INVINCIBLE 3 study, and several sites have treated patientsSeven Swiss sites are activated in the Phase 2 (INVINCIBLE-4) study for early-stage, operable Triple Negative Breast Cancer ("TNBC"), and several patients have been treatedSHELTON, Conn., Jan. 10, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or the "Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and developme

      1/10/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)

      Enrollment is ongoing and seven sites in Switzerland have been activated SHELTON, Conn. and BERN, Switzerland, Dec. 12, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors directly and increase immune system recognition of cancers, and The Swiss Group for Clinical Cancer Research SAKK ("SAKK"), a decentralized academic research institute that has been conducting clinical trials of cancer treatments in all major Swiss hospitals since 1965, announced that Andreas Muell

      12/12/24 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement

      SHELTON, Conn., Nov. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the issuance and sale of 1,237,113 shares of its common stock in a registered direct offering at a purchase price of $2.425 per share.

      11/21/24 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care